DK2757107T3 - A process for the solid phase synthesis of liraglutide - Google Patents

A process for the solid phase synthesis of liraglutide Download PDF

Info

Publication number: DK2757107T3
Authority: DK; Denmark
Prior art keywords: fmoc; resin; liraglutide; gly; solid phase
Prior art date: 2011-09-14

Application number

DK12831927.4T

Other languages

Danish (da)

English (en)

Inventor

Junfeng Pan

Jian Liu

Yaping Ma

Jiancheng Yuan

Original Assignee

Hybio Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-14

Filing date

2012-08-30

Publication date

2016-09-05

2012-08-30 Application filed by Hybio Pharmaceutical Co Ltd filed Critical Hybio Pharmaceutical Co Ltd

2016-09-05 Application granted granted Critical

2016-09-05 Publication of DK2757107T3 publication Critical patent/DK2757107T3/en

Links

108010019598 Liraglutide Proteins 0.000 title claims description 68
YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title claims description 68
229960002701 liraglutide Drugs 0.000 title claims description 68
238000000034 method Methods 0.000 title claims description 24
238000010532 solid phase synthesis reaction Methods 0.000 title claims description 19
230000008569 process Effects 0.000 title claims description 6
239000011347 resin Substances 0.000 claims description 96
229920005989 resin Polymers 0.000 claims description 96
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 40
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
238000006467 substitution reaction Methods 0.000 claims description 20
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 18
239000012071 phase Substances 0.000 claims description 14
108090000765 processed proteins & peptides Proteins 0.000 claims description 14
238000003786 synthesis reaction Methods 0.000 claims description 14
230000015572 biosynthetic process Effects 0.000 claims description 13
125000006239 protecting group Chemical group 0.000 claims description 13
239000007810 chemical reaction solvent Substances 0.000 claims description 12
230000008878 coupling Effects 0.000 claims description 12
238000010168 coupling process Methods 0.000 claims description 12
238000005859 coupling reaction Methods 0.000 claims description 12
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 12
239000003875 Wang resin Substances 0.000 claims description 11
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 claims description 11
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
238000000746 purification Methods 0.000 claims description 10
DBTMQODRSDEGRZ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-oxoethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCC=O)C3=CC=CC=C3C2=C1 DBTMQODRSDEGRZ-UHFFFAOYSA-N 0.000 claims description 9
239000004472 Lysine Substances 0.000 claims description 9
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
238000004007 reversed phase HPLC Methods 0.000 claims description 9
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
239000007790 solid phase Substances 0.000 claims description 8
230000003213 activating effect Effects 0.000 claims description 6
238000003776 cleavage reaction Methods 0.000 claims description 5
PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 claims description 5
JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 claims description 4
229960000549 4-dimethylaminophenol Drugs 0.000 claims description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
239000007822 coupling agent Substances 0.000 claims description 4
238000004108 freeze drying Methods 0.000 claims description 4
230000007017 scission Effects 0.000 claims description 4
OJBNDXHENJDCBA-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 OJBNDXHENJDCBA-QFIPXVFZSA-N 0.000 claims description 3
HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 claims description 3
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 3
239000007821 HATU Substances 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
239000012043 crude product Substances 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 49
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
238000006243 chemical reaction Methods 0.000 description 46
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 15
QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 11
NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 9
239000005457 ice water Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000011259 mixed solution Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000003746 solid phase reaction Methods 0.000 description 8
229940024606 amino acid Drugs 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
239000003643 water by type Substances 0.000 description 6
REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 5
UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 5
UCARTONYOJORBQ-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-trityloxypropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UCARTONYOJORBQ-UMSFTDKQSA-N 0.000 description 5
OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 5
DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 5
LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 5
-1 Fmoc-Val-OFI Chemical compound 0.000 description 5
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 4
238000011031 large-scale manufacturing process Methods 0.000 description 4
238000005303 weighing Methods 0.000 description 4
CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 3
WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 3
OYXZPXVCRAAKCM-SANMLTNESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OYXZPXVCRAAKCM-SANMLTNESA-N 0.000 description 3
GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000012467 final product Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012046 mixed solvent Substances 0.000 description 3
238000002390 rotary evaporation Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002699 waste material Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 2
JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 2
FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 1
KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000010170 biological method Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
- C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)

DK12831927.4T 2011-09-14 2012-08-30 A process for the solid phase synthesis of liraglutide DK2757107T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201110271342.3A CN102286092B (zh)	2011-09-14	2011-09-14	利拉鲁肽的固相合成方法
PCT/CN2012/080756 WO2013037266A1 (zh)	2011-09-14	2012-08-30	利拉鲁肽的固相合成方法

Publications (1)

Publication Number	Publication Date
DK2757107T3 true DK2757107T3 (en)	2016-09-05

Family

ID=45332864

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12831927.4T DK2757107T3 (en)	2011-09-14	2012-08-30	A process for the solid phase synthesis of liraglutide

Country Status (7)

Country	Link
US (1)	US9260474B2 (zh)
EP (1)	EP2757107B1 (zh)
CN (1)	CN102286092B (zh)
DK (1)	DK2757107T3 (zh)
ES (1)	ES2592634T3 (zh)
PL (1)	PL2757107T3 (zh)
WO (1)	WO2013037266A1 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102321170B (zh) *	2011-09-14	2013-11-13	深圳翰宇药业股份有限公司	利拉鲁肽变构体及其缀合物
CN102286092B (zh)	2011-09-14	2014-01-01	深圳翰宇药业股份有限公司	利拉鲁肽的固相合成方法
CN102584982B (zh) *	2012-02-10	2014-02-05	深圳翰宇药业股份有限公司	一种纯化固相合成利拉鲁肽粗肽的方法
EP2664374A1 (en) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
CN102875665B (zh) *	2012-09-28	2014-11-26	深圳翰宇药业股份有限公司	一种合成利拉鲁肽的方法
CN103848910B (zh) *	2012-11-30	2016-04-13	深圳翰宇药业股份有限公司	一种萨摩鲁泰的固相合成方法
CN103145828B (zh) *	2012-12-12	2014-08-13	宁波盛泰生物医药科技有限公司	一种利拉鲁肽的全固相合成方法
CN103183727B (zh) *	2012-12-17	2015-07-29	深圳翰宇药业股份有限公司	一种卷曲霉素的制备方法
CN103087181A (zh) *	2013-01-17	2013-05-08	刘卫	一种利拉鲁肽的固相合成方法
CN104045706B (zh) *	2013-03-12	2017-09-05	深圳翰宇药业股份有限公司	一种利拉鲁肽的合成方法
CN104045705B (zh) *	2013-03-12	2016-12-28	深圳翰宇药业股份有限公司	一种利拉鲁肽的合成方法
HUE033371T2 (en)	2013-03-21	2017-11-28	Sanofi Aventis Deutschland	Process for the preparation of peptide products containing a ring imide
EP2976331B1 (en)	2013-03-21	2017-03-01	Sanofi-Aventis Deutschland GmbH	Synthesis of hydantoin containing peptide products
CN103275208B (zh) *	2013-05-27	2015-04-01	成都圣诺生物制药有限公司	利拉鲁肽的制备方法
WO2014199397A2 (en) *	2013-06-11	2014-12-18	Mylan Laboratories Ltd	Process for the preparation of liraglutide
CN103304659B (zh) *	2013-06-19	2015-12-02	深圳翰宇药业股份有限公司	利拉鲁肽的固相制备方法
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
CN103980358B (zh) *	2014-01-03	2016-08-31	杭州阿诺生物医药科技股份有限公司	一种制备利拉鲁肽的方法
CN103864918B (zh) *	2014-03-31	2016-08-17	哈尔滨吉象隆生物技术有限公司	一种利拉鲁肽的固相合成方法
US20170283478A1 (en) *	2014-07-11	2017-10-05	Dr. Reddy's Laboratories Limited	Process for preparation of liraglutide
GR20140100479A (el)	2014-09-23	2016-05-05	Novetide, Ltd.,	Συνθεση λιραγλουτιδης
WO2016067271A1 (en)	2014-10-31	2016-05-06	Auro Peptides Ltd	A process for the preparation of liraglutide
CN104788546A (zh) *	2015-03-12	2015-07-22	吉尔生化（上海）有限公司	一种含有24个氨基酸残基的线性直链肽的制备方法
CN104910253A (zh) *	2015-05-15	2015-09-16	中国工程物理研究院核物理与化学研究所	作为核酸切割试剂的小肽偶联肽核酸单体组合物及其应用
CN105732798B (zh) *	2015-11-03	2018-10-02	江苏诺泰澳赛诺生物制药股份有限公司	一种利拉鲁肽的合成方法
CN106928343A (zh) *	2015-12-30	2017-07-07	深圳翰宇药业股份有限公司	索玛鲁肽的制备方法
WO2017127007A1 (en) *	2016-01-20	2017-07-27	Poypeptide Laboratories Holding (Ppl) Ab	METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3196206A1 (en) *	2016-01-20	2017-07-26	Lonza Ltd	Method for preparation of liraglutide
EP3205664A1 (en) *	2016-02-11	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Method for preparation of liraglutide using bal linker
JP6991196B2 (ja)	2016-03-23	2022-02-03	バッヘン・ホールディング・アクチエンゲゼルシャフト	グルカゴン様ペプチドを製造するための方法
WO2018032521A1 (zh)	2016-08-19	2018-02-22	深圳市健元医药科技有限公司	一种利拉鲁肽的合成方法
CN106478806B (zh) *	2016-10-24	2019-08-30	合肥国肽生物科技有限公司	一种索玛鲁肽的固相合成方法
WO2018104922A1 (en)	2016-12-10	2018-06-14	Biocon Limited	Synthesis of liraglutide
CN106699871B (zh) *	2016-12-27	2020-06-12	哈药集团技术中心	一种利拉鲁肽的制备方法
CN108264538B (zh) *	2017-01-04	2023-08-29	辽宁药联制药有限公司	门冬氨酸缩合物的固相合成方法
CN107056927B (zh) *	2017-01-16	2021-03-02	四川吉晟生物医药有限公司	一种利拉鲁肽的制备方法
CN107417771B (zh) *	2017-05-04	2021-06-29	苏州强耀生物科技有限公司	一种法尼基修饰的半胱氨酸多肽的制备方法
CN107827973A (zh) *	2017-09-15	2018-03-23	吴忠臣	一种利拉鲁肽的固相合成方法
EP3692056A1 (en)	2017-10-04	2020-08-12	Chemical & Biopharmaceutical Laboratories of Patras S.A.	A process for preparing a glucagon-like peptide
US10858414B2 (en) *	2018-03-09	2020-12-08	Enzypep B.V.	Chemo-enzymatic synthesis of semaglutide, liraglutide and GLP-1
CN110845600B (zh) *	2018-08-21	2022-12-27	鲁南制药集团股份有限公司	一种制备利拉鲁肽的方法
US11702446B2 (en)	2018-12-12	2023-07-18	Levim Biotech Llp	Acylation process for preparation of N-substituted peptide
WO2020127476A1 (en)	2018-12-19	2020-06-25	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
CN109836368B (zh) *	2019-03-14	2020-12-08	美药星（南京）制药有限公司	一种高纯度利拉鲁肽侧链的制备方法
TWI738260B (zh) *	2019-03-25	2021-09-01	台灣神隆股份有限公司	純化利拉魯肽之方法
WO2021007703A1 (en) *	2019-07-12	2021-01-21	Shanghai Space Peptides Pharmaceutical Co., Ltd.	A method for preparing liraglutide via a solid phase peptide synthesis
JP7598325B2 (ja) *	2019-09-25	2024-12-11	日産化学株式会社	ペプチド化合物の製造方法
EP3819308A1 (en)	2019-11-07	2021-05-12	Fresenius Kabi iPSUM S.r.l.	Process for the manufacture of derivatized amino acids
CN110835369A (zh) *	2019-12-02	2020-02-25	苏州天马医药集团天吉生物制药有限公司	一种合成利拉鲁肽的方法
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
WO2021130645A1 (en) *	2019-12-23	2021-07-01	Shilpa Medicare Limited	An improved process for preparation of liraglutide
CN113135989B (zh) *	2020-01-20	2023-10-03	深圳市健元医药科技有限公司	一种制备利拉鲁肽的方法
CN112321699B (zh) *	2020-11-05	2021-09-14	深圳深创生物药业有限公司	一种司美格鲁肽的合成方法
CN113150108B (zh) *	2021-05-21	2022-07-22	台州吉诺生物科技有限公司	一种利拉鲁肽的固相合成方法
WO2022266927A1 (zh) *	2021-06-24	2022-12-29	深圳翰宇药业股份有限公司	一种利拉鲁肽变构体及其制备方法、应用
CN115490750A (zh) *	2022-08-31	2022-12-20	合肥科生景肽生物科技有限公司	一种多肽合成、纯化方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
WO1999043705A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
US6451972B1 (en) *	1998-11-16	2002-09-17	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
CN1191273C (zh) *	1999-05-17	2005-03-02	康久化学公司	长效促胰岛肽
AUPR814401A0 (en) *	2001-10-08	2001-11-01	Howard Florey Institute Of Experimental Physiology And Medicine	Human 3 relaxin
CA2488348A1 (en)	2002-07-31	2004-02-05	Conjuchem Inc.	Long lasting natriuretic peptide derivatives
US7612166B2 (en) *	2004-05-21	2009-11-03	Trustees Of Tufts College	Fluorous capping reagents and methods for peptide purification
WO2008068017A1 (en) *	2006-12-09	2008-06-12	Universität Zürich Prorektorat Forschung	Coiled-coil lipopeptide helical bundles and synthetic virus-like particles
CN101555272B (zh) *	2009-04-24	2012-05-09	深圳翰宇药业股份有限公司	一种固相制备卡贝缩宫素的方法
US8907053B2 (en) *	2010-06-25	2014-12-09	Aurigene Discovery Technologies Limited	Immunosuppression modulating compounds
CN102286092B (zh)	2011-09-14	2014-01-01	深圳翰宇药业股份有限公司	利拉鲁肽的固相合成方法
CN102584982B (zh) *	2012-02-10	2014-02-05	深圳翰宇药业股份有限公司	一种纯化固相合成利拉鲁肽粗肽的方法

2011
- 2011-09-14 CN CN201110271342.3A patent/CN102286092B/zh active Active
2012
- 2012-08-30 DK DK12831927.4T patent/DK2757107T3/en active
- 2012-08-30 EP EP12831927.4A patent/EP2757107B1/en active Active
- 2012-08-30 US US14/344,660 patent/US9260474B2/en active Active
- 2012-08-30 ES ES12831927.4T patent/ES2592634T3/es active Active
- 2012-08-30 WO PCT/CN2012/080756 patent/WO2013037266A1/zh not_active Ceased
- 2012-08-30 PL PL12831927.4T patent/PL2757107T3/pl unknown

Also Published As

Publication number	Publication date
CN102286092A (zh)	2011-12-21
EP2757107A1 (en)	2014-07-23
CN102286092B (zh)	2014-01-01
EP2757107B1 (en)	2016-07-27
US9260474B2 (en)	2016-02-16
EP2757107A4 (en)	2015-04-22
ES2592634T3 (es)	2016-11-30
US20140350219A1 (en)	2014-11-27
PL2757107T3 (pl)	2016-12-30
WO2013037266A1 (zh)	2013-03-21

Publication	Publication Date	Title
DK2757107T3 (en)	2016-09-05	A process for the solid phase synthesis of liraglutide
CN103980358B (zh)	2016-08-31	一种制备利拉鲁肽的方法
US11518794B2 (en)	2022-12-06	Synthesis method for liraglutide with low racemate impurity
CN108359006B (zh)	2021-11-26	一种索玛鲁肽的制备方法
CN102875665B (zh)	2014-11-26	一种合成利拉鲁肽的方法
CN103497245B (zh)	2015-05-13	一种合成胸腺法新的方法
CN104004083B (zh)	2016-10-05	一种合成利拉鲁肽的方法
CN111670194B (zh)	2024-01-26	制备胰高血糖素肽
CN106699871A (zh)	2017-05-24	一种利拉鲁肽的制备方法
EP3433267A1 (en)	2019-01-30	Method for preparing glucagon-like peptides
CA2703113A1 (en)	2009-04-30	Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN102558338A (zh)	2012-07-11	一种合成利西拉来的方法
CN101747426B (zh)	2013-01-16	一种合成普兰林肽的方法
US20130030148A1 (en)	2013-01-31	Process for the synthesis of (aib8,35)hglp-1(7-36)-nh2
KR20210102362A (ko)	2021-08-19	플레카나타이드의 개선된 제조 방법
CN107022021A (zh)	2017-08-08	一种利拉鲁肽的固相合成法
CN106554391B (zh)	2021-11-05	一种海洋生物肽Xen2174的合成方法
CN112321699B (zh)	2021-09-14	一种司美格鲁肽的合成方法
WO2023279323A1 (zh)	2023-01-12	一种合成glp-1类似物的方法
CN105713082B (zh)	2020-12-01	一种制备利西拉来的方法
CN103936848A (zh)	2014-07-23	胸腺肽α1的合成方法
JP2008534639A (ja)	2008-08-28	Ｐｅｇ樹脂上におけるアルファ−ヘリックスのペプチド合成
CN120230189A (zh)	2025-07-01	一种司美格鲁肽杂质的合成工艺
CN119684391A (zh)	2025-03-25	一种含有柔性接头的多肽合成方法
WO2023279324A1 (zh)	2023-01-12	一种合成glp-1类似物的方法